Sue Hager is a seasoned life sciences leader. She has more than two decades of corporate affairs, government policy, advocacy and corporate finance and fundraising experience in
support of high growth biotech and life sciences organizations.
Most previously to her role at a16z, Sue served as Chief Investor Relations and Communications Officer for venture capital firm Section 32. Sue previously served as Senior Vice President of Corporate Communications, Government Affairs and Patient Advocacy for Foundation Medicine. In this role, Sue directed the stewardship of Foundation Medicine’s corporate brand, led strategic communications across the organization and directed policy and advocacy efforts focused on accelerating patient access to genomic testing in oncology. Prior to Foundation Medicine, Sue was Senior Vice President, Corporate Communications and Government Affairs for Myriant Corporation, a renewable chemicals company, where she led strategic communications and U.S. policy initiatives supporting funding and commercialization of “green” chemicals. Her efforts contributed to the financing and building of the first at-scale bio-based chemicals manufacturing plant in the US, prior to the company’s sale to PTT Global Chemical. Previously, Sue held leadership positions in life sciences organizations including Targanta Therapeutics, Coley Pharmaceutical Group and Bayer Healthcare, among others, where she led initiatives spanning corporate affairs, government affairs and policy, investor
relations, corporate and product communications, and corporate development.
Sue holds an MBA and a B.S. degree in biology with honors from Northeastern University in Boston, MA.